2024
CHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Jacobs J, Manning M, Reshef A, Yamagami K, Shetty H, Lawo J, Pollen M, Hsu F. CHARACTERIZATION OF INJECTION SITE-RELATED ADVERSE EVENTS WITH GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA. Annals Of Allergy Asthma & Immunology 2024, 133: s30-s31. DOI: 10.1016/j.anai.2024.08.121.Peer-Reviewed Original ResearchInjection-site reactionsLong-term prophylaxisHereditary angioedemaReduce treatment burdenIncidence of injection-site reactionsInjection-site adverse eventsPhase 3 clinical programTreatment burdenInjection site-relatedPlacebo-receiving patientsPhase 3 studyStudy treatment groupsFavorable safety profileLife-threatening attacksTotal disease controlOnce-monthlySafety profileAdverse eventsPhase 3Clinical studiesPatient proportionErythemaPatientsMonoclonal antibodiesPruritus
2020
Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review
Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 1875-1880.e3. PMID: 32251736, DOI: 10.1016/j.jaip.2020.03.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPlasma-derived C1-INHHereditary angioedemaC1-INHPregnant womenPlasma-derived C1 inhibitorC1 inhibitorTreatment guideline recommendationsFirst-line treatmentFavorable safety profileNumber of dosesEnglish-language articlesIntravenous plasmaGuideline recommendationsThird trimesterConsensus guidelinesSafety profileSpontaneous abortionPregnancySystematic reviewLanguage articlesAngioedemaLiterature searchData extractionTrimesterWomen